ArticleAntimicrobial agents and chemotherapy2004
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 80 citations in OpenAlex.
- Virus-Mediated Self-Assembly of Functional Cyclodextrins for Antiviral Inhibition.Angewandte Chemie (International ed. in English) · 2026Article
- Drug-Fc conjugate CD388 targets influenza virus neuraminidase and is broadly protective in mice.Nature microbiology · 2025Article
- Enhancing allosteric inhibition of dihydrodipicolinate synthase through the design and synthesis of novel dimeric compounds.RSC medicinal chemistry · 2023Article
- Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors.Journal of medicinal chemistry · 2022Article
- Antivirals Targeting the Neuraminidase.Cold Spring Harbor perspectives in medicine · 2022Review
- Development of effective anti-influenza drugs: congeners and conjugates - a review.Journal of biomedical science · 2019Review
- Double the Chemistry, Double the Fun: Structural Diversity and Biological Activity of Marine-Derived Diketopiperazine Dimers.Marine drugs · 2019Review
- The emerging influenza virus threat: status and new prospects for its therapy and control.Archives of virology · 2018Review
- Progress of small molecular inhibitors in the development of anti-influenza virus agents.Theranostics · 2017Review
- A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.The Journal of antimicrobial chemotherapy · 2014Article
- Bifunctional thiosialosides inhibit influenza virus.Bioorganic & medicinal chemistry letters · 2014Article
- Drugs to cure avian influenza infection--multiple ways to prevent cell death.Cell death & disease · 2013Review
- Newer influenza antivirals, biotherapeutics and combinations.Influenza and other respiratory viruses · 2013Review
- A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase.Chembiochem : a European journal of chemical biology · 2012Article
- Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues.Carbohydrate research · 2012Article
- Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.Journal of pharmaceutical sciences · 2011Article
- Antivirals for influenza: strategies for use in pediatrics.Paediatric drugs · 2010Review
- CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.Antimicrobial agents and chemotherapy · 2009Article
- Current and future antiviral therapy of severe seasonal and avian influenza.Antiviral research · 2008Review
- Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention.Trends in pharmacological sciences · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dimeric derivatives (compounds 7 to 9) of the influenza virus neuraminidase inhibitor zanamivir (compound 2), which have linking groups of 14 to 18 atoms in length, are approximately 100-fold more potent inhibitors of influenza virus replication in vitro and in vivo than zanamivir. The observed optimum linker length of 18 to 22 A, together with observations that the dimers cause aggregation of isolated neuraminidase tetramers and whole virus, indicate that the dimers benefit from multivalent binding via intertetramer and intervirion linkages. The outstanding long-lasting protective activities shown by compounds 8 and 9 in mouse influenza infectivity experiments and the extremely long residence times observed in the lungs of rats suggest that a single low dose of a dimer would provide effective treatment and prophylaxis for influenza virus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.